scientist

QING JANE LU, Ph.D.

650-***-**** (Home), 650-***-**** (Cell), Foster City, CA

*****@*******.***

• Extensive pharmaceutical industry experience in small molecule drug discovery/development including hit identification, lead optimization, structure-based drug design, SAR analysis, ADME, PK/PD, toxicology and IP; generated clinical and development candidates for treating inflammation, cardio arrhythmia or antibacterial agents

• Extensive experience in modern purification and characterization methodologies, skilled in HPLC (Waters, Agilent). LCMS, GILSON and ISCO systems, and interpretation of various spectra 1D/2D NMR, MS.

• Strong computer skills with experience in MS office (Word, Excel, Powerpoint), Chem-Draw/ISIS-Draw, Chem Office, SciFinder, Crossfire

PROFESSIONAL EXPERIENCE

Achaogen Inc. South San Francisco Chemistry 2006-2009

• Designed, synthesized and characterized new LpxC inhibitors, skilled in most of the analytical instruments in the lab including HPLC, LCMS, NMR and GC etc. generated potential development candidates with significant improvement on animal efficacy

Scios, Inc. (a J&J company) Fremont, CA Chemistry 1999-2006

• Designed and synthesized two first-in-class CamKII inhibitors for treating cardio arrhythmia; routinely worked in the lab and used analytical instruments to characterize small molecules; addressed issues on potency, cell activity, selectivity, stability, PK and hERG profile; advanced leads into animal efficacy study.

• Proposed, synthesized and characterize p38kinase inhibitors; optimized potency, selectivity, solubility and DMPK profiles; key contributor in generating two clinical compounds SCIO-469 (phase 2b) and SCIO-323 (phase 1) for treating rheumatoid arthritis and cancer

• Maintained a Finnegan LCMS for group use

Shaman Pharmaceuticals, S. San Francisco, CA Chemistry 1996-1998

• Designed, synthesized and scaled-up analogues to support preclinical development of an anti-diabetic drug; purified compounds on large scale HPLC

EDUCATION

Ph.D. and M.S. Synthetic Organic Chemistry, Brandeis University, Waltham, MA

B.S. Pharmaceutical Chemistry, East China Univ. of Sci. & Tech. Shanghai, P.R. China

PUBLICATIONS

1) Lu, Q.; Chen, Z.; Perumattam, J.; Wang, D-X.; Liang, W.; Xu, Y-J.; Do, S.; Bonaga, L.; Higaki, J.; Dong, H.; Liclican, A.; Sideris, S.; Laney, M.; Dugar, S.; Mavunkel, B.; Levy, D. E. “Aryl-Indolyl Maleimides as Inhibitors of CaMKII : Part 3: Importance of the indole orientation” Bioorg. Med. Chem. Lett. 2008, 18, 2399.

2) Levy, D.E; Wang, D-X.; Lu, Q.; Chen, Z.; Perumattam, J.; Xu, Y-J.; Liclican, A.; Higaki, J.; Dong, H.; Laney, M.; Mavunkel, B.; Dugar, S.; “Aryl-Indolyl Maleimides as Inhibitors of CaMKII : Part 1: SAR of the Aryl Region” Bioorg. Med. Chem. Lett. 2008, 18, 2390.

3) Levy, D. E.; Wang, D-X.; Lu, Q.; Chen, Z.; Perumattam,J.; Xu, Y-J.; Higaki, J.; Dong, H.; Liclican, A.; Laney, M.; Mavunkel, B.; Dugar, S.; “Aryl-Indolyl Maleimides as Inhibitors of CaMKII : Part 2: SAR of the Amine Tether” Bioorg. Med. Chem. Lett. 2008, 18, 2395.

4) Mavunkel, B.; Xu, Y-J.; Goyal, B.; Lim, Lu, Q.; Chen, Z.; Wang, D-X.; Higaki, J.; Chakraborty, I.; Liclican, A.; Sideris, S.; Laney, M.; Delling, U.; Catalano, R.; Higgins, L. S.; Wang, H.; Wang, J.; Feng, Y.; Dugar, S.; and Daniel E. Levy, D. E.; “Pyrimidine-based inhibitors of CaMKIId” Bioorg. Med. Chem. Lett. 2008, 18, 2404.

5) Brahn E; Schoettler N; Mavunkel B; Banquerigo ML; Medicherla S; Stebbins EG; Lu Q; Perumattam J; Dugar S; Schreiner GF; Protter AA.; “Regression of collagen-induced arthritis with an inhibitor of p38-alpha MAP kinase” Arthritis and Rheumatism 2003 48(9,S): pS346-S347

6) Lu, Q.; Ubillas, R. P.; Zhou, Y.; Dubenko, L. G.; Dener, J. M.; Bierer, D. B. “Synthetic Derivatives of Irlbacholine: A Novel Antifungal Plant Metabolite Isolated from Irlbachia alata” J. Nat. Prod. 1999, 62, 824.

7) Fort, D. M.; Litvak, J.; Lu, Q.; Phuan, P. W.; Cooper, R.; Bierer, D. E. “Isolation and Unambiguous Synthesis of Cryptolepinone: An Oxidation Artifact of Cryptolepine” J. Nat. Prod. 1998, 61, 1577.

8) Bierer, D.; Dubenko, L.; Zhang, P.; Lu, Q.; Imbach, P. A. et al. “Antihyperglycemic Activity of Cryptolepine Analogues: an Ethnobotanical Lead Structure Isolated from Cryptolepis Sanguinolenta” J. Med. Chem. 1998, 41, 2754.

9) Bierer, D.; Fort, D. M.; Mendez, C. D.; Luo, J.; Imbach, P. A.; Dubenko, L. G.; Gerber, E.; Lu, Q.; Zhang, P. et al. “Ethnobotanical-directed Discovery of the Antihyperglycemic Properties of Cryptolepine: its Isolation from Cryptolepis Sanguinolenta, synthesis and in vitro and in vivo Activities” J. Med. Chem. 1998, 41, 894.

10) Snider, B. B.; Lu, Q. “Syntheses of Raikovenal, Preraikovenal, and Epiraikovenal” Synthe. Commun. 1997, 27, 1583.

11) Snider, B. B.; Lu, Q. “Total Synthesis of Leporin A” J. Org. Chem. 1996, 61, 2839.

12) Snider, B. B.; Lu, Q. “Total Synthesis of Pyridoxatin” J. Org. Chem. 1994, 59, 8065.

13) Snider, B. B.; Lu, Q. “A Two-Step Synthesis of Pyridoxatin Analogues” Tetrahedron Lett. 1994, 35, 531.

PATENTS

1) Moser, H; Lu, Q.; Patten, P.; Wang, D.; Kasar, R.; Kaldor, S.; Patterson, B.; “Preparation of antibacterial agents” PCT Int. Appl. (2008), WO 200-***-**** A2 20081218,

2) Mavunkel, B.; Perumattam, J.; Lu, Q; Dugar S.; Goyal, B.; Wang, D.; Sarvajit C.; Luedtke, G.; Nashashibi, I.; Tester, R.; Tan, X. “Azaindole derivatives as inhibitors of p38 kinase” Pub. No.: US2005/0288299 A1, Pub. Date: Dec. 29, 2005

3) Sarvajit C.; Dugar S.; Lu, Q.; Luedtke, G.; Mavunkel, B.; Perumattam, J.; Tester, R.; “Indole-type derivatives as inhibitors of p38 kinase” PCT Int. Appl. (2004), WO 200-***-**** A2, pp117.

4) Mavunkel, B.; Sarvajit C.; Perumattam, J.; Dugar S.; Lu, Q.; Liang, X. “Benzofuran derivatives as inhibitors of p38-alpha kinase” Pub. No.: US 2003/0158417 A1, Pub. Date: Aug. 21, 2003

5) Luedtke, G.; Tester, R.; Dugar S.; Lu, Q; Perumattam, J.; Tan, X.; “Indole-type inhibitors of p38 kinase” Pub. No.: US 2003/0100588 A1, Pub. Date: May 29, 2003

6) Dugar S.; Perumattam, J.; Luedtke, G.; Tan, X.; Lu, Q; “Inhibitors of p38 kinase” Pub. No.: US 2003/0092717 A1, Pub. Date: May 15, 2003

7) Mavunkel, B.; Sarvajit C.; Perumattam, J.; Sundeep D.; Lu, Q.; Liang, X. “Indole-type derivatives as inhibitors of p38 kinase” PCT Int. Appl. (2000), WO 200******* A1, 85 pp.

8) Bierer, D. E.; Moinet, G.; Dubenko, L. G.; Botton, G.; Patereau, G.; Doare, L.; Kergoat, M.; Mesangeau, D.; Lu, Q. “Piperazine Derivatives useful as Hypoglycemic Agents” PCT Int. Appl. (1999), WO 9931096 A1, 420 pp.

POSTERS AND PRESENTATION

1) Lopez, Z.; Gomez, M.; Kostrob, C.; Armstrong. E.; Miller, G.; Reyes, N.; Lu. Q.; Moser, H.; Miller, L.; Halasohoris, S.; Mojgan. Z.; Heine, H. S.; Patten, P. “Potency and efficacy of small molecule inhibitors of the gram-negative bacterial enzyme LpxC against Yersinia Pestis and other Enterobacteriaceae” Poster presentation, the Chemical and Biological Defense Science and Technology (CBD S&T) Conference, Dallas, Texas, November 2009

2) Lopez, Z.; Gomez, M.; Armstrong. E.; Miller, G.; Reyes, N.; Lu. Q.; Moser, H.; Miller, L.; Halasohoris, S.; Mojgan. Z.; Heine, H. S.; Patten, P. “Small molecule LpxC inhibitors of Burkholderia Mallei and Burkholderia Pseudomallei: in vitro and in vivo potency and efficacy” Poster presentation, the Chemical and Biological Defense Science and Technology (CBD S&T) Conference, Dallas, Texas, November 2009

3) Lu, Q.; Mavunkel, B.; Sarvajit C.; Perumattam, J.; Luedtke, G.; Chen, Z.; Xu, Y.; Dugar, S.; Protter, A.; Schreiner, G.; “SAR and Biological Studies of Indole-type p38 Kinase Inhibitors” Poster Presentation, Gordon Research Conference, Medicinal Chemistry, New London, NH, Aug, 2005

4) Higaki, J.; Xu, Y.; Chakraborty, I.; Dong, H.; Laseki, M.; Laney, M.; Levy, D. Lu, Q.; Mavunkel, B.; Dugar, S.; Higgins, L.; “Inhibition of Calmodulin-dependant Kinase II” Poster Presentation, Structural Biology Symposium, Vanderbilt University, Tennessee, July. 2005

5) Dugar, S.; Mavunkel, B.; Sarvajit C.; Perumattam, J.; Luedtke, G.; Lu, Q.; Chen, Z.; Xu, Y.; Protter, A.; Schreiner, G.; “p38 MAP kinase inhibitors: From discovery to the clinic” Presentation, 229th ACS National Meeting, San Diego, CA, March. 2005

6) Lu, Q.; Mavunkel, B.; Sarvajit C.; Perumattam, J.; Luedtke, G.; Chen, Z.; Xu, Y.; Dugar, S.; Protter, A.; Schreiner, G.; “Discovery and biological evaluation of p38 MAP kinase inhibitors SX-011” Poster Presentation, 228th ACS National Meeting, Philadelphia, PA, Aug. 2004

7) Brahn. E.; Schoettler, Mavunkel, B.; Lu, Q.; Manquerigo, ML.; Medicherla, S.; Stebbins, L.; Perumattam, J.; Dugar, S.; Schreiner, DF.; Protter, AA. “Inhibition of Collagen-Induced Arthritis with an Inhibitor of p38 MAP Kinase” Poster Presentation, American College of Rheumatology, Orlando, Oct. 2003

Contact this candidate